Literature DB >> 27393278

Prognostic impact of RUNX1 and ETV6 gene copy number on pediatric B-cell precursor acute lymphoblastic leukemia with or without hyperdiploidy.

Nuket Yurur Kutlay1, Esra Pekpak2, Sule Altıner3, Talia Ileri2, Arzu Nedime Vicdan3, Handan Dinçaslan2, Elif Unal Ince2, Fatma Ajlan Tukun3.   

Abstract

The ETV6/RUNX1 fusion gene is a valuable prognostic marker that is frequently observed in B-cell precursor acute lymphoblastic leukemia (B-cell ALL). However, the clinical significance of copy number aberrations in these genes remains unclear. In this study, the effects of various aberrations inETV6 and RUNX1 gene copy number on disease prognosis were evaluated in 21 pediatric patients diagnosed with B-cell ALL with/without t(12;21). The prognostic significance of changes in gene copy number of ETV6 or RUNX1 in the presence or absence of hyperdiploidy, trisomy 21, and t(12;21) translocation were also evaluated. RUNX1 gene copy number amplifications were detected in 83 % of the patients who lacked t(12;21) and in all of the patients with hyperdiploidy. Trisomy 21 was detected in 78 % of the patients with hyperdiploidy. Changes in ETV6 gene copy number were detected in patients who lacked both the t(12;21) translocation and RUNX1 gene copy number amplifications. However, RUNX1 gene copy number amplification and ETV6 deletion were observed in all of the patients with t(12;21). RUNX1 gene copy number amplification was associated with hyperdiploidy, but not with t(12;21). Thus, the evaluation of distinct FISH and cytogenetic patterns in patients with B-cell ALL may strengthen the prognostic significance of changes in gene copy number.

Entities:  

Keywords:  B-cell ALL; Cancer genetics; ETV6 deletion; FISH; Hyperdiploidy; RUNX1 gain

Mesh:

Substances:

Year:  2016        PMID: 27393278     DOI: 10.1007/s12185-016-2034-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

Review 1.  Core-binding factors in haematopoiesis and leukaemia.

Authors:  Nancy A Speck; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  RUNX1 translocations and fusion genes in malignant hemopathies.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Claude Férec; Marc De Braekeleer
Journal:  Future Oncol       Date:  2011-01       Impact factor: 3.404

Review 3.  Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.

Authors:  Hironori Harada; Yuka Harada
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2005       Impact factor: 1.807

Review 4.  ETV6 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Audrey Basinko; Marc De Braekeleer
Journal:  Leuk Res       Date:  2012-05-12       Impact factor: 3.156

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

Review 6.  ETV6: a versatile player in leukemogenesis.

Authors:  Stefan K Bohlander
Journal:  Semin Cancer Biol       Date:  2005-06       Impact factor: 15.707

7.  Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  S Krentz; J Hof; A Mendioroz; R Vaggopoulou; P Dörge; C Lottaz; J C Engelmann; T W L Groeneveld; G Körner; K Seeger; C Hagemeier; G Henze; C Eckert; A von Stackelberg; R Kirschner-Schwabe
Journal:  Leukemia       Date:  2012-06-13       Impact factor: 11.528

8.  Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Vikki Rand; Helen Parker; Lisa J Russell; Claire Schwab; Hannah Ensor; Julie Irving; Lisa Jones; Dino Masic; Lynne Minto; Heather Morrison; Sarra Ryan; Hazel Robinson; Paul Sinclair; Anthony V Moorman; Jonathan C Strefford; Christine J Harrison
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

9.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Authors:  M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

Review 10.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.

Authors:  Motomi Osato
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.